Inovio因2000万美元股票发行定价而暴跌22%

• Inovio Pharmaceuticals (INO) priced an underwritten public offering expected to raise ~$20M in gross proceeds.
• The offering consists of 21.05M common shares and accompanying warrants to purchase up to 42.11M additional shares at a combined public offering price of $0.95 per share and accompanying warrant. The warrants carry an exercise price of $1.10 per share.
• The underwriter Piper Sandler a 30-day option to purchase up to an additional 3.16M shares and/or warrants to acquire up to 6.32M shares.
• The offering is expected to close on or about July 31, 2026.
• The stock price slumped about 22% on Wednesday after market hours of trading.

More on Inovio Pharmaceuticals

• Inovio Pharmaceuticals, Inc. (INO) Presents at Jefferies Global Healthcare Conference 2026 Transcript
• Inovio Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation
• Inovio: All Eyes On INO-3107 As Binary FDA Decision Looms
• INOVIO announces proposed underwritten public stock offering; shares down
• Inovio gains on late-stage trial win for DNA shot